Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
perindopril + amlodipine + atorvastatin
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Perindopril + amlodipine + atorvastatin** is an oral fixed-dose cardiovascular polypill combining the ACE inhibitor perindopril, the dihydropyridine calcium-channel blocker amlodipine, and the HMG-CoA reductase inhibitor atorvastatin. It provides simultaneous blood-pressure lowering and lipid lowering and is used as substitution therapy in adults already adequately controlled with the three components given concurrently. Marketed formulations are indicated for essential hypertension and/or stable coronary artery disease associated with primary hypercholesterolemia or mixed hyperlipidemia. The combination was developed and marketed by Servier under country-specific brands including Triveram, Lipertance, Stapressial, and Statriam; Valongix is a marketed EGIS product.
- Brand names
- LipertanceStapressialStatriamTriveramValongix
- Other names
- amlodipine + atorvastatin + perindoprilamlodipine/atorvastatin/perindoprilatorvastatin + perindopril + amlodipineatorvastatin/amlodipine/perindoprilperindopril + amlodipine + atorvastatinperindopril/amlodipine/atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on perindopril + amlodipine + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on perindopril + amlodipine + atorvastatin.